Last reviewed · How we verify

NCT06368505

Platelet-Rich Plasma Injection Versus Hydrodissection in the Treatment of Carpal Tunnel Syndrome

Recruiting now NA Last updated 16 April 2024
What this trial tests

NA trial testing ultrasound guided PRP injection in Carpal Tunnel Syndrome in 64 participants. Currently enrolling.

Timeline
16 January 2024
Primary endpoint
16 June 2024
16 July 2024

Quick facts

Lead sponsorOsama Ahmed Elshafei
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment64
Start date16 January 2024
Primary completion16 June 2024
Estimated completion16 July 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Osama Ahmed Elshafei

Who can join

Adults 18 to 65, any sex, with Carpal Tunnel Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to compare the efficacy of Ultrasound-Guided Platelet-Rich Plasma Injection versus Hydrodissection (using 2ml saline, 2ml dexamethasone and 1ml lidocaine) in the Treatment of Carpal Tunnel Syndrome. The main questions it aims to answer are: * Which modality is more effective in reducing symptoms and improving function in patients with Carpal tunnel syndrome * Asses safety profile of both methods Participants will: * Randomized to one of the two arms * Visit the clinic 1 and 3 months after intervention * Assessed for efficacy and safety of the intervention

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Carpal Tunnel Syndrome

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06368505.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing